Log In or Create Account
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Menu
Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
CROI
Conference on Bacteriophages
RWHAP CLINICAL CONFERENCE
Podcasts
Slides
Question of the Week
Guidelines
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues: Emerging Infections and Health Threats
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
HIV Drug Resistance
HIV Drug Resistance Resources
HIV Drug Resistance Mutations Chart
Recent Webinars
Journal Articles
Fellow Resources
Resources for Fellows and Others New to the HIV Field
On-Demand Webinars for Fellows
IAS-USA Guidelines and Recommendations
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Discrimination and Harassment Policy
Governance
Suggestions and Recommendations from San Francisco Locals
Donate
FAQs
Practice Question of the Week
October 26, 2026: Body Composition and Cardiovascular Risk Reduction With GLP-1 Receptor Agonists
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to both decrease weight and decrease cardiovascular events in people with and without diabetes. In people without diabetes, what proportion of the cardiovascular risk reduction is attributable to changes in body composition?
A. 10%
B. 33%
C. 67%
D. 90%
View the On-Demand Course
View Archived Questions
Leave Feedback
Subscribe
CLOSE